Item 9 Labs (INLB) – Slowly Building Up

Wednesday, May 18, 2022

Item 9 Labs (INLB)
Slowly Building Up

Item 9 Labs Corp. (OTCQX: INLB) is a vertically integrated cannabis operator and dispensary franchisor delivering premium products from its large-scale cultivation and production facilities in the United States. The award-winning Item 9 Labs brand specializes in best-in-class products and user experience across several cannabis categories. The company also offers a unique dispensary franchise model through the national Unity Rd. retail brand. Easing barriers to entry, the franchise provides an opportunity for both new and existing dispensary owners to leverage the knowledge, resources, and ongoing support needed to thrive in their state compliantly and successfully. Item 9 Labs brings the best industry practices to markets nationwide through distinctive retail experience, cultivation capabilities, and product innovation. The veteran management team combines a diverse skill set with deep experience in the cannabis sector, franchising, and the capital markets to lead a new generation of public cannabis companies that provide transparency, consistency, and well-being. Headquartered in Arizona, the company is currently expanding its operations space by up to 640,000-plus square feet on its 50-acre site, one of the largest properties in Arizona zoned to grow and cultivate flower. For additional information, visit https://investors.item9labscorp.com/.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

2Q Results. Item 9 Labs’ management announced total revenue of $6.6 million, an increase of 6% or $0.5 million over the prior year’s $6.1 million. We had forecasted $7.3 million. Gross profit was $2.7 million versus the prior year of $3.0 million. Net loss for the quarter was $3.9 million, or $0.04 per share, from last year’s net income of $49,020, or breakeven. Adjusted EBITDA decreased by $1.9 million to a loss of $0.9 million from income of $1.0 million last year.

Down the Path of Unity Rd. Highlights for Unity Rd. for the quarter include approval for plans and permitting for a dispensary in Maine, the expansion into Oklahoma in January, the first corporate owned Denver dispensary, and the asset purchase agreement for the Company’s future flagship dispensary and cultivation facility in Denver. All these events give credence to Item 9 Labs’ franchise growth strategy….

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Release – PsyBio Therapeutics Develops Commercial Purification Process for Second Generation Psycho-Targeted Compound


PsyBio Therapeutics Develops Commercial Purification Process for Second Generation Psycho-Targeted Compound

Research, News, and Market Data on PsyBio

PsyBio Therapeutics Further
Expands Scalable Manufacturing Process Development

OXFORD, Ohio and COCONUT CREEK, Fla., May 16, 2022 /CNW/ – PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) (“PsyBio” or the “Company“), a fully integrated and intellectual property driven biotechnology company developing novel, bespoke psychoactive medicinal candidates targeting the potential treatment of mental health challenges, neurological disorders and other human health conditions, today reported that it has achieved a commercially scalable purification method for one of its second generation compounds. This manufacturing process achievement is expected to enable the commercial scale purification of bioreactor produced products utilizing state of the art manufacturing methodology to further expand PsyBio’s portfolio of compounds that can be more readily and rapidly developed than competitive methods. This purification process methodology is a necessary component for the Chemistry, Manufacturing and Controls section (“CMC”) for this second-generation candidates Investigational New Drug (“IND”) application with the US Food and Drug Administration (“FDA”).

“Developing adequate and scalable methodology for the purification of pipeline compounds will allow PsyBio to enable bench scale technology to be adapted to modern biotechnological production efficiency.  This technology is necessary to produce reliable and predictable purity which allows more rapid development of large scale lots of material,” stated Michael Spigarelli, MD, PhD, MBA, PsyBio’s Chief Medical Officer. “This is expected to facilitate effective in vitro and in
vivo
 testing, moving towards additional clinical trials for psycho-targeted therapeutics intended to potentially improve mental and neurological health.”

PsyBio retains the global, exclusive, and perpetual right to license a platform technology enabling rapid generation of tryptamines and related compounds through a biosynthetic process using genetically modified bacteria and has demonstrated the ability to manufacture one of its first promising therapeutic candidates at commercial scale.    Commercial purification process development furthers the ability to manufacture compounds with predictable and reproducible purity.

“PsyBio continues to make significant progress in the manufacturing arena, developing effective and scalable techniques to enhance the ability to produce an ever-growing number of psycho-targeted therapeutic candidates in a rapid and highly cost-efficient manner,” stated Evan Levine, PsyBio’s Chief Executive Officer. “The development of this type of manufacturing processes improves PsyBio’s capability to develop and rapidly manufacture novel therapeutic agents. PsyBio remains one of the only biotechnology companies in the psychoactive therapeutic industry developing their own compounds as most of the landscape appears to rely on third party providers.”

About
PsyBio Therapeutics Corp.

PsyBio is an intellectual property driven biotechnology company developing new, bespoke, fully approved, psycho-targeted therapeutics to potentially improve mental and neurological health. The team has extensive experience in drug discovery based on synthetic biology and metabolic engineering as well as clinical and regulatory expertise progressing drugs through human studies and regulatory protocols. Research and development is currently ongoing for naturally occurring psychoactive tryptamines originally discovered in different varieties of hallucinogenic mushrooms, other tryptamines and phenethylamines and combinations thereof. The Company utilizes a bio-medicinal chemistry approach to therapeutic development, in which psychoactive compounds can be utilized as a template upon which to develop precursors and analogs, both naturally and non-naturally occurring, specifically because they are already known to have an effect within the brain.

Cautionary
Note Regarding Forward-Looking Statements

This press release contains statements that constitute “forward-looking information” (“forward-looking information“) within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking information and are based on expectations, estimates and projections as at the date of this news release. Any statement that discusses predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking information. Forward looking-statements in this press release include statements regarding: the impact of this manufacturing process achievement on commercial scale purification; the impact of this manufacturing process achievement on the CMC section of PsyBio’s IND application with the FDA; PsyBio’s ability to develop compounds more readily and rapidly than competitive methods; PsyBio’s plans for filing IND applications with the FDA; the impact of this new manufacturing on potential 
in vitro and in
vivo
 testing; PsyBio’s plans to move towards additional clinical trials for psycho-targeted therapeutics intended to potentially improve mental and neurological health; PsyBio’s ability to develop novel therapeutic agents; PsyBio’s ability to develop novel formulations to potentially treat neurologic and psychologic conditions and other disorders; PsyBio’s ability to launch clinical trials; PsyBio’s ability to build its intellectual property portfolio of novel drug candidates; PsyBio’s ability to achieve cost competitive synthesis with reduced environmental impact over current production methods; and PsyBio’s ability to move target candidates into scaled commercial manufacturing and regulatory application.

In disclosing the forward-looking information contained in this press release, the Company has made certain assumptions, including that: this manufacturing process will enable commercial scale purification of bioreactor produced products; this manufacturing process will have a positive impact on potential 
in vitro and in
vivo
 testing; this manufacturing process will have a positive impact on progress toward the filing of IND applications with the FDA; PsyBio will be successful in protecting its intellectual property; PsyBio will be successful in discovering new valuable target molecules; PsyBio will be successful in obtaining IND applications and will be able to obtain all necessary approvals for clinical trials; PsyBio will be successful in launching clinical trials; the results of preclinical safety and efficacy testing will be favorable; PsyBio’s technology will be safe and effective; a confirmed signal will be identified in PsyBio’s selected indications; and that drug development involves long lead times, is very expensive and involves many variables of uncertainty. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, it can give no assurance that the expectations of any forward-looking information will prove to be correct. Known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking information. Such factors include but are not limited to: compliance with extensive government regulations; domestic and foreign laws and regulations adversely affecting PsyBio’s business and results of operations; decreases in the prevailing process for psilocybin and nutraceutical products in the markets in which PsyBio operates; the impact of COVID-19; and general business, economic, competitive, political and social uncertainties. Accordingly, readers should not place undue reliance on the forward-looking information contained in this press release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking information to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking information or otherwise.

PsyBio makes no medical, treatment or health benefit claims about PsyBio’s proposed products. The FDA or other similar regulatory authorities have not evaluated claims regarding psilocybin and other next generation psychoactive compounds. The efficacy of such products has not been confirmed by FDA-approved research. There is no assurance that the use of psilocybin and other psychoactive compounds can diagnose, treat, cure, or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. PsyBio has not conducted clinical trials for the use of its intellectual property. Any references to quality, consistency, efficacy, and safety of potential products do not imply that PsyBio verified such in clinical trials or that PsyBio will complete such trials. If PsyBio cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the PsyBio’s performance and operations.


Baudax Bio (BXRX) – Offering Raise Helps Cash Needs Near-Term

Wednesday, May 18, 2022

Baudax Bio (BXRX)
Offering Raise Helps Cash Needs Near-Term

Baudax Bio is a pharmaceutical company focused on innovative products for acute care settings. ANJESO is the first and only 24-hour, intravenous (IV) COX-2 preferential non-steroidal anti-inflammatory (NSAID) for the management of moderate to severe pain. In addition to ANJESO, Baudax Bio has a pipeline of other innovative pharmaceutical assets including two novel neuromuscular blocking agents (NMBs) and a proprietary chemical reversal agent specific to these NMBs. For more information, please visit www.baudaxbio.com.

Gregory Aurand, Senior Research Analyst, Healthcare Services & Medical Devices, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Stock and Warrants.  Yesterday Baudax Bio announced a registered direct at-the-market offering to institutional investors for the sale and issuance of 1,646,091 shares of common stock at a price of $1.215 per share, raising close to $2 million. In conjunction, the investors, in a private placement will be issued 1,646,091 private placement warrants at an exercise price of $1.09 per share.

Timing was unexpected.  The Company had previously issued common shares in a public offering in late February 2022, so the cash need was not great at the present time.  We had expected capital raises later in 2022, even with the reduced cash burn outlook….

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Flotek Industries (FTK) – Revenues are growing but so are costs.

Wednesday, May 18, 2022

Flotek Industries (FTK)
Revenues are growing but so are costs.

Flotek Industries, Inc. creates solutions to reduce the environmental impact of energy on air, water, land and people. A technology driven, specialty green chemistry and data company, Flotek helps customers across industrial, commercial, and consumer markets improve their Environmental, Social, and Governance performance. Flotek’s Chemistry Technologies segment develops, manufactures, packages, distributes, delivers, and markets high-quality cleaning, disinfecting and sanitizing products for commercial, governmental and personal consumer use. Additionally, Flotek empowers the energy industry to maximize the value of their hydrocarbon streams and improve return on invested capital through its real-time data platforms and green chemistry technologies. Flotek serves downstream, midstream, and upstream customers, both domestic and international. Flotek is a publicly traded company headquartered in Houston, Texas, and its common shares are traded on the New York Stock Exchange under the ticker symbol “FTK.” For additional information, please visit www.flotekind.com.

Michael Heim, CFA, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Revenues are rising as industry conditions improve. Flotek reported a 6% year-over-year increase in revenues in the 2022 first quarter as drilling activity accelerated in February and March reaching the highest levels since the pandemic. Results were above our expectations for revenues of $11.8 million. As a reminder, the company’s business partnership with Profrac did not begin until April 1, 2022 and did not have an effect on the quarter. 

Cost are rising faster. Cost of Goods Sold rose 11% year over year. Flotek reports higher supply costs associated with freight and other factors. Management vowed to address rising costs by “adjusting prices accordingly” but also concedes that competitive pressures remain very tight. Adjusted EBITDA for the quarter was ($5.5) million versus ($6.6) million for the same period last year and ($5.7) million in the December quarter. …

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Grindrod Shipping (GRIN) – Grindrod sells vessel, exercises option to acquire another

Wednesday, May 18, 2022

Grindrod Shipping (GRIN)
Grindrod sells vessel, exercises option to acquire another

Grindrod Shipping operates a fleet of owned and long-term and short-term chartered-in drybulk vessels predominantly in the handysize and supramax/ultramax segments. The drybulk business, which operates under the brand “Island View Shipping” (“IVS”), includes a Core Fleet of 31 vessels consisting of 15 handysize drybulk carriers and 16 supramax/ultramax drybulk carriers. The Company also owns one medium range product tanker on bareboat charter. The Company is based in Singapore, with offices in London, Durban, Tokyo, Cape Town and Rotterdam. Grindrod Shipping is listed on NASDAQ under the ticker “GRIN” and on the JSE under the ticker “GSH”.

Michael Heim, CFA, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Grindrod Shipping announced the sale of the medium range product tanker, Matuku, for $30 million. The tanker was the last of its medium range tankers as the company completes a shift to dry shipping. Grindrod will exercise a purchase option under her existing lease financing at a cost of $25.4 million netting $4.6 million in cash.

Simultaneously, Grindrod is exercising an option to purchase the IVS Pinehurst for $18 million. The Pinehurst is currently being in-chartered. We believe the company will be able to finance the purchase of Pinehurst without seeking external financing given its cash on hand ($100 million at yearend) and expected proceeds from the Matuku sale. Finally, Grindrod agreed to extend the long-term charter of the IVS Crimson Creek for a period of 11-13 months at a net charter-in rate of $26,276 per day. …

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Release – QuoteMedia Wins Contract as Market Data Provider for The Motley Fool



QuoteMedia Wins Contract as Market Data Provider for The Motley Fool

Research, News, and Market Data on QuoteMedia

PHOENIX, May 18, 2022 (GLOBE NEWSWIRE) — QuoteMedia, Inc. (OTCQB: QMCI), a leading provider of market data and financial applications, announced an agreement with The Motley Fool to provide a wide-ranging suite of market data feed services and financial applications to power their extremely popular and influential fool.com website.

Founded in 1993 by brothers Tom and David Gardner, The Motley Fool’s purpose is to make the world smarter, happier, and richer. Through its website, fool.com, The Motley Fool provides free and premium investment guidance to millions of individual investors around the world, including:

  • Premium membership services that provide stock recommendations, detailed analysis of companies, model portfolios, live streaming video during market hours, and more
  • Free market news and commentary with hundreds of new articles published each week
  • Member-only tools and programming for building an ideal portfolio, tracking performance, and monitoring companies of interest

“We are constantly working to improve our products and services to ensure that we are providing tools that help make the world smarter, happier and richer. It is vital that we provide the best possible financial information and analytical market data content to educate and empower our audience,” said Mark Kennedy, Global Tech and Operations Lead for The Motley Fool. “QuoteMedia has been a joy to work with. Their broad array of accurate, timely market data and information content is remarkable, and the functionality and ease of integration of their content applications made them a clear choice for our online platforms. Most impressive of all, though, was the level of service they provide. QuoteMedia really went above and beyond to ensure we were able to meet our goals.”

“Since 1993, The Motley Fool has been a trusted source of investment and financial advice to millions of individual investors,” said Dave Shworan, CEO of QuoteMedia. “The fool.com website is certainly a premiere destination for individuals looking for reliable and trustworthy financial information and guidance. We are very pleased to have been chosen as their data provider, and we’re glad to be joining The Motley Fool in delivering the highest possible quality content to their audience.”

About The Motley Fool

Founded in 1993 in Alexandria, Va., by brothers David and Tom Gardner, The Motley Fool Holdings, Inc. is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people around the globe every day through its innovative investing solutions, podcasts, books, newspaper columns, media appearances, and non-profit The Motley Fool Foundation. For more information, visit www.fool.com .

About QuoteMedia

QuoteMedia is a leading software developer and cloud-based syndicator of financial market information and streaming financial data solutions to media, corporations, online brokerages, and financial services companies. The Company licenses interactive stock research tools such as streaming real-time quotes, market research, news, charting, option chains, filings, corporate financials, insider reports, market indices, portfolio management systems, and data feeds. QuoteMedia provides industry leading market data solutions and financial services for companies such as the Nasdaq Stock Exchange, TMX Group (TSX Stock Exchange), Canadian Securities Exchange (CSE), London Stock Exchange Group, FIS, U.S. Bank, Broadridge Financial Systems, JPMorgan Chase, CI Financial, Canaccord Genuity Corp., Hilltop Securities, HD Vest, Stockhouse, Zacks Investment Research, The Motley Fool, General Electric, Boeing, Bombardier, Telus International, Business Wire, PR Newswire, FolioFN, Regal Securities, ChoiceTrade, Cetera Financial Group, Dynamic Trend, Inc., Qtrade Financial, CNW Group, IA Private Wealth, Ally Invest, Inc., Suncor, Virtual Brokers, Leede Jones Gable, Firstrade Securities, Charles Schwab, First Financial, Cirano, Equisolve, Stock-Trak, Mergent, Cision, Day Trade Dash and others. Quotestream®, QMod™ and Quotestream Connect™ are trademarks of QuoteMedia. For more information, please visit www.quotemedia.com .

QuoteMedia Investor Relations

Brendan Hopkins
Email: 
investors@quotemedia.com
Call: (407) 645-5295


AI Navigating Intersections Through Trial and Error


Image Credit: MIT News


On the Road to Cleaner, Greener, and Faster Driving

No one likes sitting at a red light. But signalized intersections aren’t just a minor nuisance for drivers; vehicles consume fuel and emit greenhouse gases while waiting for the light to change.

What if motorists could time their trips so they arrive at the intersection when the light is green? While that might be just a lucky break for a human driver, it could be achieved more consistently by an autonomous vehicle that uses artificial intelligence to control its speed.

In a new study, MIT researchers demonstrate a machine-learning approach that can learn to control a fleet of autonomous vehicles as they approach and travel through a signalized intersection in a way that keeps traffic flowing smoothly.

Using simulations, they found that their approach reduces fuel consumption and emissions while improving average vehicle speed. The technique gets the best results if all cars on the road are autonomous, but even if only 25 percent use their control algorithm, it still leads to substantial fuel and emissions benefits.

“This is a really interesting place to intervene. No one’s life is better because they were stuck at an intersection. With a lot of other climate change interventions, there is a quality-of-life difference that is expected, so there is a barrier to entry there. Here, the barrier is much lower,” says senior author Cathy Wu, the Gilbert W. Winslow Career Development Assistant Professor in the Department of Civil and Environmental Engineering and a member of the Institute for Data, Systems, and Society (IDSS) and the Laboratory for Information and Decision Systems (LIDS).

Intersection Intricacies

While humans may drive past a green light without giving it much thought, intersections can present billions of different scenarios depending on the number of lanes, how the signals operate, the number of vehicles and their speeds, the presence of pedestrians and cyclists, etc.

Typical approaches for tackling intersection control problems use mathematical models to solve one simple, ideal intersection. That looks good on paper, but likely won’t hold up in the real world, where traffic patterns are often about as messy as they come.

Wu and Jayawardana shifted gears and approached the problem using a model-free technique known as deep reinforcement learning. Reinforcement learning is a trial-and-error method where the control algorithm learns to make a sequence of decisions. It is rewarded when it finds a good sequence. With deep reinforcement learning, the algorithm leverages assumptions learned by a neural network to find shortcuts to good sequences, even if there are billions of possibilities.

This is useful for solving a long-horizon problem like this; the control algorithm must issue upwards of 500 acceleration instructions to a vehicle over an extended time period, Wu explains.

“And we have to get the sequence right before we know that we have done a good job of mitigating emissions and getting to the intersection at a good speed,” she adds.

But there’s an additional wrinkle. The researchers want the system to learn a strategy that reduces fuel consumption and limits the impact on travel time. These goals can be conflicting.

“To reduce travel time, we want the car to go fast, but to reduce emissions, we want the car to slow down or not move at all. Those competing rewards can be very confusing to the learning agent,” Wu says.

While it is challenging to solve this problem in its full generality, the researchers employed a workaround using a technique known as reward shaping. With reward shaping, they give the system some domain knowledge it is unable to learn on its own. In this case, they penalized the system whenever the vehicle came to a complete stop, so it would learn to avoid that action.

Traffic Tests

Once they developed an effective control algorithm, they evaluated it using a traffic simulation platform with a single intersection. The control algorithm is applied to a fleet of connected autonomous vehicles, which can communicate with upcoming traffic lights to receive signal phase and timing information and observe their immediate surroundings. The control algorithm tells each vehicle how to accelerate and decelerate.

Their system didn’t create any stop-and-go traffic as vehicles approached the intersection. (Stop-and-go traffic occurs when cars are forced to come to a complete stop due to stopped traffic ahead). In simulations, more cars made it through in a single green phase, which outperformed a model that simulates human drivers. When compared to other optimization methods also designed to avoid stop-and-go traffic, their technique resulted in larger fuel consumption and emissions reductions. If every vehicle on the road is autonomous, their control system can reduce fuel consumption by 18 percent and carbon dioxide emissions by 25 percent, while boosting travel speeds by 20 percent.

“A single intervention having 20 to 25 percent reduction in fuel or emissions is really incredible. But what I find interesting, and was really hoping to see, is this non-linear scaling. If we only control 25 percent of vehicles, that gives us 50 percent of the benefits in terms of fuel and emissions reduction. That means we don’t have to wait until we get to 100 percent autonomous vehicles to get benefits from this approach,” she says.

Down the road, the researchers want to study interaction effects between multiple intersections. They also plan to explore how different intersection set-ups (number of lanes, signals, timings, etc.) can influence travel time, emissions, and fuel consumption. In addition, they intend to study how their control system could impact safety when autonomous vehicles and human drivers share the road. For instance, even though autonomous vehicles may drive differently than human drivers, slower roadways and roadways with more consistent speeds could improve safety, Wu says.

While this work is still in its early stages, Wu sees this approach as one that could be more feasibly implemented in the near-term.

“The aim in this work is to move the needle in sustainable mobility. We want to dream, as well, but these systems are big monsters of inertia. Identifying points of intervention that are small changes to the system but have significant impact is something that gets me up in the morning,” she says. 

Reprinted with permission of MIT News (http://news.mit.edu/)


Suggested Content



Edge Computing Can Take AI Out of the Cloud and to the Moon



Edge Computing Importance to AI Applications





One Stop Systems (OSS) NobleCon18 Presentation Replay



Motorsport Games (MSGM) NobleCon18 Presentation Replay

 

Stay up to date. Follow us:

 

Newrange Gold (NRGOF) – Newrange Rethinks its Portfolio; New Acquisitions Contemplated

Wednesday, May 18, 2022

Newrange Gold (NRGOF)
Newrange Rethinks its Portfolio; New Acquisitions Contemplated

Newrange is focused on district-scale exploration for precious metals in the prolific Red Lake District of northwestern Ontario. The past-producing high-grade Argosy Gold Mine is open to depth, while the adjacent North Birch Project offers additional blue-sky potential. Focused on developing shareholder value through exploration and development of key projects, the Company is committed to building sustainable value for all stakeholders. Further information can be found on our website at www.newrangegold.com .

Mark Reichman, Senior Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

North Birch drilling program. At the North Birch Project, northeast of Red Lake, Ontario, two diamond drill holes were completed for a total of 723 meters. While the winter drill program was cut short due to inclement weather, the drill holes were the first two to test the main target horizon. Management remains optimistic based on commonalities between North Birch and other gold systems within the Uchi sub-province. Recall that the first diamond drill hole on the primary target horizon confirmed the presence of a strong deformation zone greater than 100 meters wide. The sheared and folded basalts and iron formation displayed moderate to high carbonate alteration, and local quartz veining. Newrange anticipates drilling to resume in the summer.

Next steps at Argosy. Recall that Newrange owns a 100% interest in the Argosy property which hosts the past producing Argosy gold mine and is adjacent to North Birch. The first drill sites at Argosy have been prepared, and initial holes will test both the down-dip extension of gold mineralization below the historic mine workings and parallel to veins closer to surface….

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Release – Baudax Bio to Present at the H.C. Wainwright Annual Global Life Sciences Conference



Baudax Bio to Present at the H.C. Wainwright Annual Global Life Sciences Conference

Research, News, and Market Data on Baudax Bio


MALVERN, Pa., May 18, 2022 (GLOBE NEWSWIRE) — Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on innovative products for acute care settings, today announced that Gerri Henwood, the Company’s President and Chief Executive Officer, will present at the H.C. Wainwright Annual Global Life Sciences Conference, taking place in Miami, Florida on Wednesday, May 25, 2022, at 1:30 p.m. Eastern Time.

A webcast of the presentation will be available on the “Events” page within the investors section of the Baudax Bio website at 
https://www.baudaxbio.com/news-and-investors. The webcast will be archived on the company’s website for 90 days following the event.

About Baudax Bio

Baudax Bio is a pharmaceutical company focused on innovative products for acute care settings. ANJESO is the first and only 24-hour, intravenous (IV) COX-2 preferential non-steroidal anti-inflammatory (NSAID) for the management of moderate to severe pain. In addition to ANJESO, Baudax Bio has a pipeline of other innovative pharmaceutical assets including two novel neuromuscular blocking agents (NMBs) and a proprietary chemical reversal agent specific to these NMBs. For more information, please visit www.baudaxbio.com.

CONTACT:

Investor Relations Contact:

Argot Partners
Sam Martin / Kaela Ilami
(212) 600-1902
baudaxbio@argotpartners.com

Media Contact:

Argot Partners
David Rosen
(212) 600-1902
david.rosen@argotpartners.com


Release – Baudax Bio Announces $2.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules



Baudax Bio Announces $2.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Research, News, and Market Data on Baudax Bio


MALVERN, Pa., May 17, 2022 (GLOBE NEWSWIRE) — Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for acute care settings, today announced that it has entered into a definitive agreement with certain institutional investors for the issuance and sale of 1,646,091 shares of its common stock, at a purchase price of $1.215 per share, in a registered direct offering priced at-the-market under Nasdaq rules. The Company also agreed to issue to the investors, in a concurrent private placement, unregistered warrants to purchase up to 1,646.091 shares of its common stock.

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

The warrants have an exercise price of $1.09 per share, will be exercisable immediately upon issuance and will expire five years from the date of issuance. The closing of the offering is expected to occur on or about May 19, 2022, subject to the satisfaction of customary closing conditions.

The gross proceeds from the offering are expected to be approximately $2.0 million before deducting placement agent fees and other offering expenses. Baudax Bio currently intends to use the net proceeds from the offering for the commercialization of ANJESO®, pipeline development activities and general corporate purposes.

The shares of common stock described above (but not the warrants or shares of common stock underlying the warrants) are being offered by the Company in a registered direct offering pursuant to an effective “shelf” registration statement on Form S-3 (Registration No. 333-253117), including an accompanying base prospectus previously filed with the Securities and Exchange Commission (the “SEC”) on February 16, 2021 which became effective on September 2, 2021. The offering of such shares of common stock is being made only by means of a prospectus supplement that forms a part of the registration statement. A final prospectus supplement and the accompanying base prospectus relating to the registered direct offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. Electronic copies of the prospectus supplement and the accompanying base prospectus may also be obtained, when available, by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 1002, by phone at (212) 856-5711 or e-mail at 
placements@hcwco.com.

The warrants described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Act”) and, along with the shares of common stock underlying the warrants, have not been registered under the Act, or applicable state securities laws. Accordingly, the warrants and underlying shares of common stock may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable state securities laws.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About
Baudax Bio

Baudax Bio is a pharmaceutical company focused on innovative products for acute care settings. ANJESO is the first and only 24-hour, intravenous (IV) COX-2 preferential non-steroidal anti-inflammatory (NSAID) for the management of moderate to severe pain. In addition to ANJESO, Baudax Bio has a pipeline of other innovative pharmaceutical assets including two novel neuromuscular blocking agents (NMBs) and a proprietary chemical reversal agent specific to these NMBs. For more information, please visit www.baudaxbio.com.

Forward
Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties. Such forward-looking statements reflect Baudax Bio’s expectations about its future performance and opportunities that involve substantial risks and uncertainties. When used herein, the words “anticipate,” “believe,” “estimate,” “may,” “upcoming,” “plan,” “target,” “goal,” “intend,” and “expect,” and similar expressions, as they relate to Baudax Bio or its management, are intended to identify such forward-looking statements. Forward-looking statements may include, without limitation, statements regarding the expected completion and use of proceeds of the offering. These forward-looking statements are based on information available to Baudax Bio as of the date of publication on this internet site, including statements relating to the expected completion and use of proceeds of the registered direct offering, and are subject to a number of risks, uncertainties, and other factors that could cause Baudax Bio’s performance to differ materially from those expressed in, or implied by, these forward-looking statements. These risks and uncertainties include, among other things, risks related to market and other conditions, the ongoing economic and social consequences of the COVID-19 pandemic, Baudax Bio’s ability to advance its current product candidate pipeline through pre-clinical studies and clinical trials, Baudax Bio’s ability to raise future financing for continued development of its product candidates such as BX1000, BX2000 and BX3000, Baudax Bio’s ability to pay its debt and satisfy conditions necessary to access future tranches of debt, Baudax Bio’s ability to comply with the financial and other covenants under its credit facility, Baudax Bio’s ability to manage costs and execute on its operational and budget plans, Baudax Bio’s ability to achieve its financial goals; and Baudax Bio’s ability to obtain, maintain and successfully enforce adequate patent and other intellectual property protection. These forward-looking statements should be considered together with the risks and uncertainties that may affect Baudax Bio’s business and future results included in Baudax Bio’s filings with the Securities and Exchange Commission at www.sec.gov. These forward-looking statements are based on information currently available to Baudax Bio, and Baudax Bio assumes no obligation to update any forward-looking statements except as required by applicable law.

CONTACT:

Investor Relations Contact:
Argot Partners
Sam Martin / Kaela Ilami
(212) 600-1902
baudaxbio@argotpartners.com

Media Contact:
Argot Partners
David Rosen
(212) 600-1902
david.rosen@argotpartners.com 


Is the Bear Market Bull?


Image Credit: Forextime (Flickr)


The Battle Between Bull and Bear Has Become Intense

A bull facing off with a bear is among the most entrenched icons and lore in stock market trading. Bull vs. bear icons can be found in almost any office that is involved in the stock market. Long ago, people came to use the terms “bullish” and “bearish” to reflect their thoughts on market direction, and the meanings are universally understood. In 2022 the memes of bulls and bears struggling with each other have reached a crescendo. After an incredibly long and strong market from Spring 2020 until year-end 2021, there has been no question we were in a bull market. As we entered 2022, the sentiment which drives markets has been less confident and decidedly more negative.

The terms are based on direction and overall sentiment, but over time, analysts have attempted to define what a bear market is. In recent years, a bear market has been defined as having fallen 20% or more from recent highs.


Source: Koyfin

The chart above shows the volatility index (%) against
the S&P 500 index (%). Since December 2021, the index has hit higher highs
and higher lows as the markets are wrestling with more negativity than prior
periods.

 

Bull and Bear Facing Off

In a bear market, share prices are on average dropping each week. This results in a downward trend that investors believe will continue; the belief, in turn, snowballs into an entrenched downward trend.

To date (May 18), none of the major indices have fallen 20% or more from their high. But for many in the markets, it feels as though they have. Investors had been velocitized by the swift gains over the prior years, so even sideways movement for a period would feel negative. The current 16% decline of the S&P 500 feels much steeper than it is. It has been held up by many strong up days showing there are still plenty of bottom-fishing bulls. This is the essence of the bull and bear facing off.

Bullish Position

The economy may seem to have the ingredients for a reduction in growth that could lead to a reduction in corporate earnings, but the most followed measurement, employment, isn’t showing signs of faltering. Confidence is created by knowing if one wants a job, they can get a job. Job growth and wages have been marching higher through most of 2022. So much so, that wage inflation is becoming a concern.

There is still ample stimulus in the system as a result of quantitative easing and low-interest rates. The Fed has discontinued adding stimulus in the form of bond purchases and has begun raising rates, but real rates are still negative, and the mopping up of money injected into the system is scheduled and will follow a slow timeline.

Consumers are still spending. Retail sales for April rose a seasonally adjusted 0.9% in April. Demand is strong for most goods and services, especially those involving leisure activities. With the consumer still looking to spend, the markets may hold up well.

Bearish Position

Fed Chair Jerome Powell gave a talk yesterday at the Wall
Street Journal’s Future of Everything Festival.
During his talk, he discussed his resolve to bring down the 40-year high inflation rate and bring it in line with their 2% target range. He admitted that the landing might be bumpy, but he believes it can be done without causing a recession. A recession is generally defined as two consecutive quarters of negative growth (GDP). We are now halfway through the second quarter of the year. The first quarter, which came off a very strong 4th quarter, showed the economy had negative growth of 1.6%. So we may already be in a recession. If job growth falters, it will become a problem.

The Fed is raising rates and draining stimulus with an eventual target of 2% inflation. This would seem to argue for aggressively applying of the economic brake pedal.

Higher rates increase costs for businesses that borrow money and slow down purchases for households that were planning on making a purchase on credit. For businesses, higher rates could cut into profits, and households may decide to curtail purchases because of the high cost of money (borrowing costs).

Take-Away

By definition, it is premature to call this market a bear market, yet it has ceased to be a bull market. On up days, the bulls come out in force and have driven the markets up by 2% or more in a trading session. This shows that there are many positive participants buying in at these lower prices. The bearish sentiment is in large part based on future expectations, not economic reports. The feeling is based on previous Fed tightenings and the heightened probability of entering a recession.

This market has continued to surprise over the previous decade, and the future won’t be any different. In addition to overall growth or recession, there is the potential for a rolling recession. This could play out where it affects companies that rely on low interest rates such as housing, while at the same time those that still prosper while the job market is good and continues to grow. Examples of this are sectors where people spend disposable income on things such as leisure, entertaining, or clothing. In the meantime, the bulls and bears are thrashing to determine how 2022 will play out in the markets.

Paul Hoffman

Managing Editor, Channelchek

Suggested Content



Protecting Portfolios from Losses While Capturing Gains



Finding Tomorrow’s Best Stocks Beneath a Cloak of Invisibility




Where are Consumers Most Likely to Spend Their Leisure Budget?



Asset Classes that Perform Best and Worst with Negative Real Interest Rates

Sources

https://www.bea.gov/data/gdp/gross-domestic-product

https://www.wsj.com/articles/feds-powell-to-take-wsj-questions-on-inflation-and-economic-outlook-11652779802?mod=Searchresults_pos7&page=1

www.koyfin.com

Stay up to date. Follow us:

 

Release – Salem Media to Present at the Singular Research Spring Select Webinar



Salem Media to Present at the Singular Research Spring Select Webinar

Research, News, and Market Data on Salem Media

IRVING, Texas–(BUSINESS WIRE)– Salem Media
Group
, Inc. (NASDAQ: SALM), announced today that it will present virtually at the Singular Research Spring Select Webinar on Wednesday, May 25th at 12:00 PM Central Time. The presentation will be available on the investor relations portion of the company’s website www.salemmedia.com prior to the company’s presentation.

ABOUT SINGULAR RESEARCH

Singular Research aims to be the most trusted supplier of independent, trusted, single-sources research on small-to-micro cap companies to the small-to-medium sized Hedge Fund manager. Singular Research provides quarterly updates for 40 to 70 companies and makes recommendations.

Singular strives to achieve goals by finding under or overvalued securities. Singular’s goal is to provide initiation reports and quarterly updates for approximately 40 micro-to-small cap companies. In most cases, Singular analysts research companies that are not covered by any other firms.

Singular provides honest advice. Independent analysts have no financial interest in the stocks covered. Analysts are compensated based on the accuracy of their research calls not through trading commissions or potential deal flow.

ABOUT SALEM MEDIA GROUP

Salem Media Group is America’s leading multimedia company specializing in Christian and conservative content, with media properties comprising radio, digital media and book and newsletter publishing. Each day Salem serves a loyal and dedicated audience of listeners and readers numbering in the millions nationally. With its unique programming focus, Salem provides compelling content, fresh commentary and relevant information from some of the most respected figures across the Christian and conservative media landscape. Learn more about Salem Media Group, Inc. at www.salemmedia.comFacebook and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220517006118/en/

Evan D. Masyr
Executive Vice President and Chief
Financial Officer
(805) 384-4512
evan@salemmedia.com

Source: Salem Media Group, Inc.

Released May 18, 2022


Release – Cocrystal Pharma to Present at the H.C. Wainwright Global Investment Conference



Cocrystal Pharma to Present at the H.C. Wainwright Global Investment Conference

Research, News, and Market Data on Cocrystal Pharma


BOTHELL, Wash., May 18, 2022 (GLOBE NEWSWIRE)
— 
Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that James Martin, Chief Financial Officer and co-interim Chief Executive Officer, will present a Company overview at the H.C. Wainwright Global Investment Conference on Wednesday, May 25, 2022 at 10:00 a.m. Eastern Time. The hybrid in-person and virtual conference is being held at the Fontainebleau Miami Beach Hotel in Miami Beach.

A webcast of the presentation will be available live on the IR Calendar of the Company website and will be archived for 90 days following the event.

About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.

Investor Contact:
LHA Investor Relations
Jody Cain
310-691-7100

jcain@lhai.com

Media Contact:
JQA Partners
Jules Abraham
917-885-7378

Jabraham@jqapartners.com